Get started
Author

Eduardo J. Pennella

Observed names: E Pennella, E. J. Pennella, E. Pennella, E.J. Pennella, Eduardo J Pennella, Eduardo Pennella
Institution: Merus (Netherlands)
Observed institutions: Northwestern University, Rush University Medical Center, Roswell Park Comprehensive Cancer Center, University of California, Los Angeles, Eli Lilly (United States), University of Pittsburgh, Sarah Cannon, MaxCyte (United States), Merus (Netherlands), Mylan (United States), Viatris
ORCID: 0000-0002-1697-9220
Observed ORCID: 0000-0002-1697-9220
OpenAlex ID: A5082560000
PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
2013 · Jyoti D. Patel, Mark A. Socinski, et al. · Journal of Clinical Oncology · 373
PDF
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer
2016 · Hope S. Rugo, Abhijit Barve, et al. · JAMA · 146
PDF
Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
2009 · Jyoti D. Patel, Philip Bonomi, et al. · Clinical Lung Cancer · 66
Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma.
2020 · Christina M. Annunziata, Armin Ghobadi, et al. · Journal of Clinical Oncology · 34
A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL‐1401O vs. EU‐trastuzumab and US‐trastuzumab
2018 · Cornelius F. Waller, Apinya Vutikullird, et al. · British Journal of Clinical Pharmacology · 31
A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim
2018 · Cornelius F. Waller, Renger G. Tiessen, et al. · Journal of Cancer Research and Clinical Oncology · 31
Brain Metastases as the Primary Site of Relapse in Two Randomized Phase III Pemetrexed Trials in Advanced Non–Small-Cell Lung Cancer
2011 · Waldo Ortuzar, Nasser Hanna, et al. · Clinical Lung Cancer · 30
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia
2019 · Cornelius F. Waller, Gopinath M. Ranganna, et al. · Annals of Hematology · 25
PDF
Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer
1996 · E. Roca, E. Pennella, et al. · European Journal of Cancer · 23
Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.
2024 · Jerome Fayette, Florian Clatot, et al. · Journal of Clinical Oncology · 22
PDF
An exploratory subgroup analysis of race and gender in squamous cancer of the head and neck: Inferior outcomes for African American males in the LORHAN database
2014 · D. Neil Hayes, Guangbin Peng, et al. · Oral Oncology · 22
Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.
2016 · Hope S. Rugo, Abhijit Barve, et al. · Journal of Clinical Oncology · 19
Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial.
2025 · Carla M.L. van Herpen, Amaury Daste, et al. · Journal of Clinical Oncology · 17
Abstract CT012: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)
2023 · Ezra E. Cohen, Jérôme Fayette, et al. · Cancer Research · 14
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
2021 · Hope S. Rugo, Eduardo J. Pennella, et al. · Breast Cancer Research and Treatment · 14
PDF
411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial
2024 · C. Le Tourneau, J. Fayette, et al. · Annals of Oncology · 13
PDF
Pemetrexed in head and neck cancer: A systematic review
2013 · Athanassios Argiris, Eduardo Pennella, et al. · Oral Oncology · 12
Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial.
2019 · Cornelius F. Waller, Aleksei Manikhas, et al. · Journal of Clinical Oncology · 8
Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab
2016 · H. Rugo, A. Barve, et al. · Annals of Oncology · 8
Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial.
2018 · Aleksei Manikhas, Eduardo J. Pennella, et al. · Journal of Clinical Oncology · 7
Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non–Small-Cell Lung Cancer
2014 · Craig H. Reynolds, Jyoti D. Patel, et al. · Clinical Lung Cancer · 7
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial
2021 · Hope S. Rugo, Eduardo J. Pennella, et al. · The Breast · 6
PDF
A bioequivalence study of proposed bevacizumab biosimilar, MYL-1402O (A) vs EU-Avastin (B) and US-Avastin (C).
2017 · Mark A. Socinski, Matthew Hummel, et al. · Journal of Clinical Oncology · 6
Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.
2016 · Hope S. Rugo, Abhijit Barve, et al. · Journal of Clinical Oncology · 6
A pharmacokinetics (PK) bioequivalence trial of proposed trastuzumab biosimilar, Myl-1401O (A) vs EU-Herceptin (B) and US-Herceptin (C)
2017 · C. Waller, A. Vutikullird, et al. · European Journal of Cancer · 5
Works count: 52
Citation count: 986
H-index: 14
I10-index: 17
Year
Topic
Type